The Retrospective Analysis About The Treatment With Iguratimod And Methotrexate For Patients With Active Rheumatoid Arthritis

Objective:To evaluate and compare the efficacy and safety of iguratimod and methotrexate for the treatment of rheumatoid arthritis (RA), by observing the differences iguratimod (IMD) and methotrexate (MTX) alone and combined with clinical manifestations use in treating rheumatoid arthritis (RA) patients, routine laboratory tests, and other immunological parameters, the analysis its efficacy and safety data.Methods:The RA patients who the clinical course and background characteristics in line with the elevant conditions were seleted.They were randomly divided into a control group and study group. The patients in study group were treated with iguratimod plus MTX.And divided the control group as alone IMD treatment group and alone MTX treatment group. Periodic reviewed of relevant laboratory parameters and to assess the clinical outcome measures at 4,8,12,16,24 weeks. Focuses on treated after 4 and 24 weeks of each group compared with the baseline of its efficacy and safety parameters.Results:All patients after treatment-related symptoms had been improved to a certain extent.The rate of the observation group (IMD+MTX) to reach ACR20/50/70 ratio was significantly higher than the control groups(P<0.05),the IMD group was superior than the MTX group.When after 24 weeks treatment, the combination of IMD with MTX was superior to monotherapy with iguratimod or MTX. And also, the combination of iguratimod with MTX did not significantly increase the risk of infection liver damage. The main adverse events were observed during the entire treatment leukopenia, thrombocytopenia, elevated liver transaminases, gastrointestinal tract and upper respiratory tract infection, three groups of adverse events had no significant difference. These adverse events were mostly mild or moderate, could be improved after withdrawal, no deaths occurred in all patients.Conclusion:Iguratimod(IMD) for rheumatoid arthritis treatment is effectived,its onset time is shorter than methotrexate (MTX). To some extent, the combination of IMD with MTX have a synergistic effect.